LENZ Therapeutics (LENZ) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 63.4% versus a loss of 90.0%. Over five years, VYGR leads with a -50.0% price change compared with -95.6% for LENZ. Voyager Therapeutics is the larger company by market cap ($95.2 million vs $93.2 million), about 1.0 times the size.
Voyager Therapeutics converts more of its revenue into profit, with a net margin of -296.5% versus -430.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | VYGR |
|---|---|---|
| Share price | $2.97 | $1.53 |
| Market cap | $93.16M | $95.21M |
| 1-day change | -11.23% | -4.97% |
| YTD return | -81.47% | -61.07% |
| 1-year return | -89.97% | -63.40% |
| 5-year return | -95.57% | -50.00% |
| EPS (TTM) | $-4.53 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $19.09M | $40.37M |
| Revenue growth (YoY) | — | -49.53% |
| Net income (latest FY) | $-82.13M | $-119.72M |
| Gross margin | 97.81% | — |
| Operating margin | -477.46% | -326.56% |
| Net margin | -430.25% | -296.53% |
| 52-week high | $32.13 | $5.48 |
| 52-week low | $2.80 | $1.48 |
| Distance from 52-week high | -90.77% | -72.08% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +400.17% | +829.41% |
| Average volume | 892.30K | 770.24K |
| Shares outstanding | 31.42M | 62.23M |
| Employees | 40 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VYGR has outperformed LENZ by 26.6 percentage points over the past year.
- Voyager Therapeutics is more profitable, keeping -296.5 cents of every revenue dollar as net income versus -430.3 cents for LENZ Therapeutics.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
LENZ vs VYGR FAQ
Which is bigger, LENZ Therapeutics or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $95.21M compared with $93.16M for LENZ Therapeutics (LENZ).
Which stock has performed better over the past year, LENZ or VYGR?
VYGR returned -63.40% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.